DK1458713T3 - Indolinonderivater anvendelige som proteinkinaseinhibitorer - Google Patents

Indolinonderivater anvendelige som proteinkinaseinhibitorer

Info

Publication number
DK1458713T3
DK1458713T3 DK02796035T DK02796035T DK1458713T3 DK 1458713 T3 DK1458713 T3 DK 1458713T3 DK 02796035 T DK02796035 T DK 02796035T DK 02796035 T DK02796035 T DK 02796035T DK 1458713 T3 DK1458713 T3 DK 1458713T3
Authority
DK
Denmark
Prior art keywords
sup
kinase inhibitors
protein kinase
derivatives useful
indolinone derivatives
Prior art date
Application number
DK02796035T
Other languages
Danish (da)
English (en)
Inventor
Jonathan W Wray
John H Griffin
Roger Briesewitz
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of DK1458713T3 publication Critical patent/DK1458713T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK02796035T 2001-12-27 2002-12-20 Indolinonderivater anvendelige som proteinkinaseinhibitorer DK1458713T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34381301P 2001-12-27 2001-12-27
US34374601P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1458713T3 true DK1458713T3 (da) 2005-10-31

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02796035T DK1458713T3 (da) 2001-12-27 2002-12-20 Indolinonderivater anvendelige som proteinkinaseinhibitorer

Country Status (21)

Country Link
US (3) US6686362B2 (https=)
EP (1) EP1458713B1 (https=)
JP (1) JP4363985B2 (https=)
KR (1) KR100965519B1 (https=)
CN (1) CN1290844C (https=)
AT (1) ATE302771T1 (https=)
AU (1) AU2002360753B2 (https=)
BR (1) BR0215360A (https=)
CA (1) CA2470480C (https=)
CO (1) CO5611126A2 (https=)
DE (1) DE60205776T2 (https=)
DK (1) DK1458713T3 (https=)
ES (1) ES2247411T3 (https=)
HU (1) HUP0500111A3 (https=)
IL (1) IL162203A0 (https=)
MX (1) MXPA04006271A (https=)
NO (1) NO327550B1 (https=)
NZ (1) NZ533219A (https=)
PL (1) PL208283B1 (https=)
RU (1) RU2316554C2 (https=)
WO (1) WO2003057690A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4588447B2 (ja) * 2002-08-09 2010-12-01 セラヴァンス, インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
JP2007509173A (ja) 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
KR101443651B1 (ko) 2005-10-18 2014-09-23 얀센 파마슈티카 엔.브이. Flt-3 키나제의 억제 방법
NZ572073A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
BRPI0710548B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
CA2663147A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
IN2015DN00659A (https=) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JP6290884B2 (ja) 2012-08-07 2018-03-07 ヤンセン ファーマシューティカ エヌ.ベー. c−FMSキナーゼ阻害剤の調製プロセス
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
CN107001283B (zh) 2014-07-31 2021-05-25 国家健康与医学研究院 Flt3受体拮抗剂
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
BR112019008762A2 (pt) 2016-11-02 2019-07-16 Arog Pharmaceuticals, Inc. método para o tratamento de um distúrbio proliferativo mutado em flt3
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
IL143920A0 (en) 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
JP2004502686A (ja) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド 4−ヘテロアリール−3−ヘテロアリーリデニル−2−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
AU8544901A (en) 2000-08-18 2002-03-04 Cor Therapeutics Inc Quinazoline derivatives as kinase inhibitors
EP1349852A2 (en) 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones
JP4588447B2 (ja) 2002-08-09 2010-12-01 セラヴァンス, インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Also Published As

Publication number Publication date
US7060703B2 (en) 2006-06-13
CN1290844C (zh) 2006-12-20
MXPA04006271A (es) 2004-10-04
EP1458713A1 (en) 2004-09-22
RU2004122918A (ru) 2005-03-27
US20060142281A1 (en) 2006-06-29
RU2316554C2 (ru) 2008-02-10
AU2002360753B2 (en) 2008-08-21
US6686362B2 (en) 2004-02-03
ES2247411T3 (es) 2006-03-01
CN1608063A (zh) 2005-04-20
BR0215360A (pt) 2004-12-14
IL162203A0 (en) 2005-11-20
CA2470480C (en) 2010-12-14
KR100965519B1 (ko) 2010-06-23
CA2470480A1 (en) 2003-07-17
DE60205776D1 (en) 2005-09-29
US20030171378A1 (en) 2003-09-11
KR20040070283A (ko) 2004-08-06
CO5611126A2 (es) 2006-02-28
DE60205776T2 (de) 2006-06-14
HUP0500111A3 (en) 2009-10-28
PL208283B1 (pl) 2011-04-29
ATE302771T1 (de) 2005-09-15
AU2002360753A1 (en) 2003-07-24
JP2005514420A (ja) 2005-05-19
US7223783B2 (en) 2007-05-29
US20040198804A1 (en) 2004-10-07
WO2003057690A1 (en) 2003-07-17
HK1068886A1 (en) 2005-05-06
NO327550B1 (no) 2009-08-10
NO20042926L (no) 2004-07-08
PL369602A1 (en) 2005-05-02
NZ533219A (en) 2005-10-28
EP1458713B1 (en) 2005-08-24
JP4363985B2 (ja) 2009-11-11
HUP0500111A2 (hu) 2005-07-28

Similar Documents

Publication Publication Date Title
DK1458713T3 (da) Indolinonderivater anvendelige som proteinkinaseinhibitorer
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
CY1108032T1 (el) Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
ATE554087T1 (de) Neue kinaseinhibitoren
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
EA200901601A1 (ru) Производные пиридазинона
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
BRPI0407841A (pt) inibidores heterocìclicos de quinase
MX2008002104A (es) Derivados de 1-acildihidropirazol.
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
BR0307903A (pt) derivados de arilsulfona
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
MXPA04005809A (es) Inhibidores de proteinas quinasas.